ReviewNature communications2026
Microbial engraftment and immune regulation during fecal microbiota transplantation and immune checkpoint inhibitor therapy.
Review in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The gut microbiota is a critical determinant of both therapeutic efficacy and immune-related toxicity during cancer immunotherapy with immune checkpoint inhibitors (ICIs). Fecal microbiota transplantation (FMT) has emerged as a strategy to introduce beneficial microbial functions, yet clinical outcomes remain variable. In this Review, we integrate evidence from recent clinical trials combining FMT with ICIs in a mechanism-based framework for understanding this variability and to guide safer clinical applications. We discuss how specific microbial functional programs can either buffer or lower thresholds for immune dysregulation and outline implications for donor selection, longitudinal monitoring, and trial design in oncology.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.